TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7840553
Drug: Dapsone monotherapy
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone monotherapy
Study: 3302061
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (including dapsone monotherapy)
Study: 31203378
Drug: Liraglutide (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (0.06 mg)
Study: 31203378
Drug: Exenatide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (0.5 μg)
Study: 31203378
Drug: Liraglutide (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (0.06 mg) with exendin-(9,39) pretreatment
Study: 25743734
Drug: EASE program
Normalized name: BOIL-EASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: EASE program (3 weeks duration, including a 570-minute group meeting and telephone counseling twice a week)
Study: 23735098
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy (18 hours/week for 6 months)
Study: 21705689
Drug: Oral palmitoyl-ethanolamide
Normalized name: Palmitoyl ethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral palmitoyl-ethanolamide (PEA) 300-mg tablets twice a day
Study: 21705689
Drug: Placebo (PEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PEA vehicle tablets twice a day)
Study: 8405695
Drug: Acipimox (slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (slow-release formulation)
Study: 8405695
Drug: Acipimox (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (administered every 2 hours for 4 days)
Study: 3530849
Drug: Nicardipine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (0.5 mg)
Study: 30690860
Drug: DBBM +
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBBM + L‐PRF (test)
Study: 28601864
Drug: Higher Protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher Protein Diet (HPD) 1.34 g/kg body weight
Study: 28601864
Drug: Standard Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Protein Diet (SPD) 0.8 g/kg body weight
Study: 26661283
Drug: Conventional antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antibiotic treatments
Study: 26621715
Drug: D-cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-cycloserine (DCS) 100 mg
Study: 22992332
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) 400 mg
Study: 19673649
Drug: Rapid virologic
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid virologic clearance and low-level viremia (HCV RNA level, <400,000 IU/mL)
Study: 19673649
Drug: Complete viral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete viral suppression after 4 weeks of treatment (RVR)
Study: 16699278
Drug: Rifaximin-based triple
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin-based triple therapy (rifaximin 400 mg t.i.d., esomeprazole 40 mg o.d., clarithromycin 500 mg b.i.d.)
Study: 16699278
Drug: Levofloxacin-based therapy
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin-based therapy (levofloxacin 500 mg o.d.)
Study: 15041399
Drug: EC‐MPS 720
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC‐MPS 720 mg b.i.d.
Study: 11458721
Drug: Urapidil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (25 mg)
Study: 11458721
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 ml isotonic saline)
Study: 9916608
Drug: Maalox 30
Normalized name: Maalox
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maalox 30 mL given 2 hours before sparfloxacin
Study: 9916608
Drug: Maalox 30
Normalized name: Maalox
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maalox 30 mL given 2 hours after sparfloxacin
Study: 9916608
Drug: Maalox 30
Normalized name: Maalox
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maalox 30 mL given 4 hours after sparfloxacin
Study: 2914634
Drug: HCl solutions
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCl solutions (pH 1, 1.5, 2, 2.5, 3, 4, 5, and 6) infused at 8 ml/min
Study: 26996270
Drug: Higher medication
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher medication adherence self‐efficacy
Study: 1532445
Drug: Estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol valerate (2 mg, days 1-21) + Medroxyprogesterone acetate (10 mg, days 12-21)
Study: 1532445
Drug: 17 beta-estradiol
Normalized name: 17 beta-estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta-estradiol (1.5 mg, days 1-24) + Desogestrel (150 micrograms, days 13-24)
Study: 1532445
Drug: All hormone-treated
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All hormone-treated groups
Study: 3925217
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 240 mg daily (6 X 40 mg)
Study: 30251943
Drug: Intraoperative antithymocyte
Normalized name: antithymocyte immunoglobulin (rabbit)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative antithymocyte globulin infusion via coronary sinus
Study: 30251943
Drug: Traditional antithymocyte
Normalized name: antithymocyte immunoglobulin (rabbit)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional antithymocyte globulin infusion after implantation
Study: 29111960
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg enteric-coated aspirin daily
Study: 27368439
Drug: Pranlukast (leukotriene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast (leukotriene antagonist) administered for up to 28 days along with antibiotics.
Study: 27368439
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received antibiotic-based conventional treatment according to guidelines.
Study: 24568906
Drug: Huangqi injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huangqi injection (0.5-1.0 mL/kg per day) by intravenous infusion
Study: 24568906
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride injection (control)
Study: 23941474
Drug: Lithium added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium added to current therapy
Study: 23941474
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy without lithium
Study: 16174073
Drug: Antiviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral therapy (combined interferon (IFN; 3 or 5 million units of IFN alpha‐2b thrice weekly) plus ribavirin (1000‐1200 mg per day) for 24‐48 weeks)
Study: 8851377
Drug: 10 micrograms.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms.kg‐1 intrathecal morphine (Group A)
Study: 8851377
Drug: 20 micrograms.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms.kg‐1 intrathecal morphine (Group B)
Study: 8851377
Drug: 30 micrograms.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 micrograms.kg‐1 intrathecal morphine (Group C)
Study: 1626757
Drug: Terbutaline Turbuhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline Turbuhaler (0.5 mg qid)
Study: 1626757
Drug: Albuterol chlorofluorocarbon
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol chlorofluorocarbon (CFC) inhaler (0.2 mg qid)
Study: 1626757
Drug: Preference for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preference for albuterol CFC inhaler
Study: 31305232
Drug: Behavioral medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral medicine treatment (BMT)
Study: 24731671
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg eprotirome
Study: 24731671
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg eprotirome
Study: 20491818
Drug: Early implant
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early implant placement (healing sites)
Study: 20491818
Drug: Conventional implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional implant placement (healed sites)
Study: 20491818
Drug: Both early
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both early and conventional implant placements
Study: 18562772
Drug: Carbohydrate gel
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate gel (0.24 g/kg body mass)
Study: 12799094
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 mg daily for 2 weeks, increased to 80 mg if BP remained >/=130/85 mm Hg)
Study: 12799094
Drug: Telmisartan (titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (titration from 40 mg to 80 mg)
Study: 2227222
Drug: Gallopamil slow
Normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil slow release (100 mg, twice daily)
Study: 2227222
Drug: Gallopamil immediate
Normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil immediate release (50 mg, four times daily)
Study: 337985
Drug: Oral droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral droperidol plus diazepam
Study: 337985
Drug: Droperidol syrup
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Droperidol syrup
Study: 28521109
Drug: 22,600 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22,600 ppm fluoride varnish, toothbrush, a 50-mL tube of 1,450 ppm fluoride toothpaste, and standardized prevention advice
Study: 23332800
Drug: yoghurt enriched
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: yoghurt enriched with 3 g n‐3 LC‐PUFA/d
Study: 23332800
Drug: yoghurt enriched
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: yoghurt enriched with 0.8 g n‐3 LC‐PUFA/d
Study: 18053049
Drug: Phosphatidylcholine/sodium deoxycholate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylcholine/sodium deoxycholate preparation
Study: 16427861
Drug: Cold-blood cardioplegia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-blood cardioplegia enriched with N-acetylcysteine (50 mg per kilogram of body weight)
Study: 9126183
Drug: UP +
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: UP + CB + weekly chlorhexidine rinse (CHX)
Study: 8463520
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg tid for 12 weeks
Study: 3948897
Drug: Glucagon (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (1 mg bolus followed by 2 mg/h continuous infusion for 8 h)
Study: 15765628
Drug: Continuous estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous estradiol 1 mg/day plus intermittent norgestimate 90 microg/day
Study: 6793276
Drug: Systemically given
Normalized name: TITANIUM DIOXIDE 7.75 g in 100 mL / ZINC OXIDE 10 g in 100 mL TOPICAL CREAM [Give Me Shade Sunscreen Broad Spectrum SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemically given antibiotics
Study: 24521108
Drug: Pramipexole 0.5
Normalized name: pramipexole 0.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 0.5 mg
Study: 26765470
Drug: Therapeutic vaccine
Normalized name: COVID-19 Therapeutic Vaccine - Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic vaccine (YIC)
Study: 24844551
Drug: Topical cooling
Normalized name: Castiva Cooling Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cooling with 4°C saline (Group I)
Study: 24844551
Drug: Mild hypothermic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild hypothermic cardiopulmonary bypass (28‐32°C) without topical cooling (Group II)
Study: 22540524
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg daily for three months (after initial oral bolus of 300 mg) together with aspirin 75 mg
Study: 22540524
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg daily alone
Study: 19595629
Drug: Dopaminergic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic treatment (pramipexole)
Study: 19595629
Drug: Pre-treatment condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment condition (no dopaminergic treatment)
Study: 16261945
Drug: Sabal-urtica preparation
Normalized name: Urtica preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sabal-urtica preparation PRO 160/120
Study: 12123338
Drug: GEP (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEP (gemcitabine 1000 mg/m2, epirubicin 90 mg/m2, paclitaxel 175 mg/m2)
Study: 12123338
Drug: EP (epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP (epirubicin 90 mg/m2, paclitaxel 175 mg/m2)
Study: 12123338
Drug: Epirubicin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin alone (90 mg/m2)
Study: 9021203
Drug: 3.375 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.375 g of piperacillin-tazobactam intravenously every 6 hours
Study: 9021203
Drug: 4.5 g
Normalized name: Zosyn 4.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 g of piperacillin-tazobactam intravenously every 8 hours
Study: 9021203
Drug: 3.1 g
Normalized name: ticarcillin/K clavulanate 3.1 gram INTRAVEN VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.1 g of ticarcillin-clavulanate intravenously every 6 hours
Study: 9021203
Drug: 3.0 g
Normalized name: LACTIC ACID 23.0 g in 1 L TOPICAL SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g of ampicillin-sulbactam intravenously every 6 hours
Study: 3351705
Drug: Locally prepared
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locally prepared milk‐free formulation (group A)
Study: 3351705
Drug: Spray dried
Normalized name: peptone,dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray dried commercial cow's milk formula (group B)
Study: 26536315
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral emtricitabine/tenofovir disoproxil fumarate for HIV prevention
Study: 26536315
Drug: Community and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community and partner discouragement regarding the study pill
Study: 26536315
Drug: Limited acceptability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limited acceptability of the pill's attributes
Study: 24637965
Drug: Low-protein experimental
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein experimental formula (EXPL) with 1.65 g of protein/100 kcal
Study: 24637965
Drug: Control formula
Normalized name: Anti Acne Control Formula Top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control formula (CTRL) with 2.7 g of protein/100 kcal
Study: 22231734
Drug: Cevimeline 30
Normalized name: Cevimeline 30mg Oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cevimeline 30 mg orally 3 times daily for 6 weeks
Study: 22231734
Drug: Placebo orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally 3 times daily for 6 weeks
Study: 16466011
Drug: Fasting insulin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting insulin, IL-6, TNFalpha, and HOMA-IR index in type 2 diabetic patients
Study: 10707793
Drug: Rituximab 375
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m2/week for 4 weeks
Study: 10170451
Drug: Pressurised metered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurised metered dose inhaler (pMDI)
Study: 8113480
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (B)
Study: 8113480
Drug: Information-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information-based therapy (A1)
Study: 3533340
Drug: Pharmacological ionisation
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological ionisation with pirprofen (two-dose levels)
Study: 27566696
Drug: 25 μg vaginal
Normalized name: Mycelex-G Vaginal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg vaginal misoprostol
Study: 23812762
Drug: Alcohol (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.6 g/kg for men, 0.55 g/kg for women)
Study: 16439370
Drug: Fondaparinux 2.5
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 2.5 mg subcutaneously once daily for six to 14 days
Study: 14749738
Drug: Neither supplement
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither supplement
Study: 9403285
Drug: Mefloquine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine with food (750 mg)
Study: 9403285
Drug: Mefloquine without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine without food (750 mg)
Study: 7912285
Drug: Intradermal injections
Normalized name: Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injections of di‐Lex (III3FucnLc4) for 6 months
Study: 7912285
Drug: Intradermal injections
Normalized name: Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injections of tumor associated carbohydrate antigen (TCA) for 6 months
Study: 7912285
Drug: Intradermal injections
Normalized name: Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injections of monomeric Lex
Study: 29706321
Drug: Resveratrol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (150 mg/day)
Study: 28898473
Drug: Prucalopride (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride (4 mg oral)
Study: 26990378
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec (IDeg) add-on to liraglutide
Study: 16626797
Drug: Proactive telephone-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive telephone-based peer counseling intervention with up to 6 counseling calls and nicotine replacement therapy (NRT) patches if prepared to quit smoking
Study: 16626797
Drug: Demographic variables
Normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demographic variables (females, White), higher daily smoking rate, poorer perceived health and moderate perceived risk of smoking
Study: 1716810
Drug: Salmonella typhi
Normalized name: Salmonella Typhi Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmonella typhi Ty21a/V. cholerae Inaba (EX210) vaccine
Study: 29898692
Drug: Twice-weekly sessions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly sessions of protocolized interpersonal psychotherapy (IPT)
Study: 29898692
Drug: Twice-weekly sessions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly sessions of cognitive behavioral therapy (CBT)
Study: 29898692
Drug: Once-weekly sessions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly sessions of protocolized IPT and CBT
Study: 26435055
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy (10-day regimen)
Study: 26435055
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (10-day regimen)
Study: 20536957
Drug: Self-monitoring of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-monitoring of blood glucose (SMBG) using premixed insulin lispro mixtures
Study: 20536957
Drug: Self-monitoring of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-monitoring of blood glucose (SMBG) using basal insulin glargine
Study: 18728175
Drug: Lifestyle modification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle modification + OCs + Metformin
Study: 18728175
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment and placebo
Study: 15717881
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention + insulin treatment (L+I)
Study: 15717881
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment alone (I)
Study: 12187204
Drug: Transurethral resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral resection plus 100 mg epirubicin
Study: 7869850
Drug: New generation
Approvals — FDA: no, EMA: no, PMDA: no
Description: New generation combined oral contraceptives (OC)
Study: 7869850
Drug: Oral protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral protein load in OC users
Study: 787014
Drug: Fenoprofen calcium
Normalized name: Fenoprofen Calcium
DrugBank: Fenoprofen (DB00573)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenoprofen calcium (200, 400, or 600 mg)
Study: 787014
Drug: Propoxyphene napsylate
Normalized name: Propoxyphene Napsylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propoxyphene napsylate (50, 100, or 150 mg)
Study: 31495887
Drug: β-blocker use
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blocker use (eGFR >60)
Study: 31495887
Drug: β-blocker use
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blocker use (eGFR 30-60)
Study: 31495887
Drug: β-blocker use
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blocker use (eGFR <30)
Study: 25233649
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of acupuncture at Xiaojie point and tendon regulation manipulation